RedeFin Capital

Insights

Research Reports

Main Site

Tag: equity research

  • Sector Analysis: Emerging Themes in Indian Equities

    Sector Analysis: Emerging Themes in Indian Equities

    Indian equity sector analysis 2026 reveals a market at an inflection point. Nifty 50 trading at ~24,000+ levels reflects institutional optimism tempered by valuation caution. Six months into FY26, patterns are crystallising across sectors-and I’ve identified seven areas commanding attention from institutional investors, policy makers, and capital allocators. This is not a forecast. This is a reading of where capital is actually flowing, where regulation is tightening, and where technical fundamentals justify conviction.

    Why Sector Rotation Matters Right Now

    The Indian equity market in 2026 operates under three structural headwinds and one tailwind. Headwinds: FII selling pressure (net outflows ₹1.2 lakh Cr in 2024), persistent inflation volatility, and geopolitical risk premium. The tailwind: Domestic Institutional Investors (DII) absorbing ₹2.5 lakh Cr+ net buying, signalling local capital’s confidence in differentiated sector plays.

    Under these conditions, broad index buying is increasingly reckless. Sector selection becomes the margin of safety. The seven sectors analysed below separate signal from noise.

    1. AI & Technology: From Consumption to Creation

    Market Opportunity: India’s AI market expected to reach $17 billion by 2027. Current size: ~$8.5B. CAGR: 26%+.

    India’s technology sector has historically been consumption-heavy: captive software services for Western clients, business process outsourcing, staff augmentation. That model is breaking. Three drivers:

    • GenAI adoption at scale: TCS, Infosys, and HCL are embedding LLM-native services into their delivery models. TCS reported ₹8,500+ Cr in GenAI-related revenue pipeline as of Q3 FY26. Infosys committed $500M+ in AI skilling. This is margin-accretive, not cannibalistic.
    • Domestic enterprise spend: Indian manufacturers, fintech firms, and e-commerce platforms are building in-house AI capabilities. This creates supply-side constraints for talent and premium pricing on specialist consulting.
    • IP ownership shift: Tech majors are licensing proprietary models, not just renting engineering. Patent filing from Indian tech firms up 34% YoY (2024-25 data).
    Key Play: TCS, Infosys, HCL. Secondary: Wipro, Tech Mahindra. The sector will bifurcate: premium generalists win; undifferentiated cost-plus players compress margins.

    2. Renewables & Clean Energy: Target Met, Scale Pending

    Capacity Target: 500 GW by 2030. Current installed: ~250 GW (solar ~70 GW, wind ~45 GW). Capex required: ₹15+ lakh Cr by 2030.

    The renewable sector has moved from “aspirational policy” to “structural necessity.” Three factors crystallise conviction:

    • Tariff floor formation: Solar tariffs bottomed at ₹2-2.50/kWh. Wind at ₹3.20-3.60/kWh. Bidding discipline is now disciplined-no suicide bids. Margins for quality operators (Adani Green, NTPC Green, Tata Power) are stabilising at 12-15% EBITDA margins.
    • Manufacturing market: Domestic solar module manufacturing capacity now 25+ GW annually. Cell capacity ramping. This insulates operators from import tariff volatility and Chinese competition.
    • Buyer creditworthiness: Offtake from state power distributors improving. Collections cycles compressing. DISCOM debt issues are being addressed via bailout schemes and operational reforms.
    Key Plays: Adani Green (3.5+ GW operational, 7+ GW under construction), NTPC Green (13+ GW capacity, margin expansion phase), Tata Power Renewable (2.5+ GW). Watch: Thermax, Kalpataru Power for BOP (balance of plant) capex.

    3. Defence & Aerospace: Localisation Hitting Inflection

    Production Scale: Defence production ₹1.27 lakh Cr in FY25. Exports: ₹21,000 Cr (10%+ YoY growth). Target: ₹60,000 Cr exports by 2030.

    India’s defence sector is no longer a “protect domestic industry” play. It’s becoming a manufacturing platform. Policy tailwinds are real and sticky:

    • Import substitution with teeth: Armed Forces procurement rules now mandate 40-50% indigenous content on new contracts. Existing suppliers being forced to localise. This creates pricing power for domestic tier-1 and tier-2 players.
    • Export momentum: ₹21,000 Cr in FY25 means drones, missiles, avionics, and ordnance are reaching Middle East, South Africa, Philippines. These are repeat orders. Margins on defence exports run 18-22% EBITDA.
    • Capex at scale: ₹2+ lakh Cr earmarked for modernisation in Defence Ministry capex plans (2025-35 horizon). This flows to HAL, BEL, Mazagon Dock, and private tier-1s like Bharat Dynamics.
    Key Plays: HAL (order backlog ₹2.7+ lakh Cr), BEL (₹35,000+ Cr backlog), Mazagon Dock (ship-building margin expansion). Secondary: Bharat Dynamics (missiles), Hindustan Aeronautics (aerospace).

    4. Pharmaceuticals & Healthcare: Scale + Margin Resilience

    Market Size: Indian pharma market valued at ₹2.5 lakh Cr (domestic + exports combined). Growth: 10-12% CAGR through FY27.

    Pharma has been punished by valuation multiple compression-not by fundamentals deterioration. The sector is actually improving operationally:

    • Biosimilar exports booming: Indian firms capturing 40%+ of global biosimilar volume. Cipla, Lupin, and Sun Pharma are scaling monoclonal antibody and enzyme replacement therapy exports. Unit economics run 35-40% gross margins.
    • Domestic market sharpening: Hospital consolidation (Max, Apollo, Fortis) driving utilisation. Pharma benefit from diagnostic procedures and elective surgery volume. Chronic disease prevalence (diabetes, hypertension) remains tailwind.
    • Regulatory stability: DCGI approvals, WHO-GMP compliance, and product registration timelines have stabilised. Surprise regulation risk has retreated. Patent cliff post-2026 is absorbed into guidance already.
    Key Plays: Cipla (biosimilar momentum), Lupin (insulin franchise + exports), Sun Pharma (specialty pharma, APIs), Dr. Reddy’s (chronic disease, generics volume). Watch: Biocon (biotech exposure).

    5. Financials: Credit Growth with Collateral Strength

    Credit Momentum: Bank credit growth at 14-16%. NPAs at decade lows: 1.1-1.3% of advances. Consumer lending: 12-15% CAGR.

    The financial sector divides into three buckets worth separating:

    • Banks (Tier-1): HDFC Bank, ICICI Bank, Axis Bank benefit from rising credit cycle without deteriorating asset quality. Deposits are sticky (DII inflows driving CASA ratios higher). NIM compression is real but manageable at 2.8-3.0%. RoE expansion from 16%+ achievable through cost use.
    • NBFCs (Housing Finance & Consumer): LIC Housing Finance, HDFC Bank-wait, HDFC merged with HDFC Bank. Pure plays: Bajaj Housing, PNB Housing. These firms are riding loan-to-value (LTV) compression (borrowers are equity-heavy) and margin improvement. Cost of funds falling. Spreads widening.
    • Insurance: Life insurance premiums up 18%+ YoY. ULIP products capturing market share from mutual funds due to tax efficiency. LIC’s market share holding at 60%. Private insurers (HDFC Life, ICICI Prudential, Max Life) growing 25%+ but at tighter underwriting. Valuation multiples: 3-4x P/E (depressed). Upside: 25-35% over 18 months if equity market stabilises.
    Key Plays: HDFC Bank (deposit franchise, loan growth), Axis Bank (digital leadership, CASA momentum), ICICI Bank (treasury gains + credit growth). NBFC: Bajaj Housing, Affordable Housing focus. Insurance: LIC, HDFC Life.

    6. Infrastructure: Capex Tailwind, Valuation Gap

    Union Budget Allocation: ₹11.11 lakh Cr capex earmarked in Union Budget 2025-26. Roads, railways, ports, airports dominate. Capex as % of GDP: 3.5%+ (highest in emerging markets).

    Infrastructure capex is no longer discretionary. It’s embedded in fiscal policy. Three sectors within infrastructure matter:

    • Roads & Highways: L&T Infra has ₹1.3+ lakh Cr order backlog. Toll revenues recovering. Road construction PKR (per km rate) stable at ₹2.5-3.5 Cr/km. Margins: 12-15% EBITDA for quality players. L&T margin guidance: 12%+ achievable by FY27.
    • Railways & Metro: Indian Railways capex ₹2.4 lakh Cr in FY26 budget. Metro expansion in 35+ cities. Siemens, Bombardier, and local players like Texmaco Rail capturing orders. Order backlog >₹15,000 Cr across majors.
    • Real Estate & Construction Materials: UltraTech Cement expanding capacity (+25M tonnes by 2026). Cement realisations at ₹550-650/bag depending on region. Volume growth 8-10% CAGR. Concrete players benefit. Flooring tile demand (residential, commercial) up 15%+ YoY.
    Key Plays: L&T (order backlog, margin expansion), UltraTech Cement (capacity + pricing power), Kalyani Forge (specialty steel), Shree Cement (regional advantage). Watch: IL&FS Transportation (toll upside).

    7. Consumer & Discretionary: Consumption Structurally Shifting

    Market Opportunity: India’s consumption market positioned to exceed $2 trillion+ by 2030. Current: ~$1.2 trillion. Urban middle class: 150M+ households.

    Consumer is fractured into sub-stories. Blanket index buying is folly. Segment by segment:

    • Quick Commerce & Logistics: Blinkit, Zepto, Dunzo redefined last-mile delivery. Traditional FMCG margins compressing (retailers losing share to quick-commerce). Listed players like Titan (watches, jewellery) benefit from premiumisation. ITC (FMCG + hotels) has margin headroom.
    • Automobiles: EV penetration at 5-6% of annual passenger vehicle sales. Tata Motors and Mahindra pivot to EV scale. Traditional ICE margin compression real. BYD and Li-Auto partnerships signal foreign EV makers coming. Winners: EV native players (Tata, Mahindra). Losers: regional ICE-only makers.
    • Hospitality & Leisure: Indian Hotels (Taj), Oberoi, Marriott India benefiting from leisure travel growth (+20% YoY). Room rates and occupancy up. REVPAR (revenue per available room) expansion cycles. Gaming & online entertainment (though unlisted) seeing 30%+ growth.
    • Fashion & Apparel: Tier-1 brands (Aditya Birla Fashion, Arvind) seeing 15%+ comparable growth. Fast fashion (Uniqlo, H&M) disrupting traditional retail. Margin pressure on mid-tier players. Manyavar, Biba benefiting from occasion wear for weddings (growing ₹12,000+ Cr market).
    Key Plays: Titan (watches, jewellery, EOU premiumisation), Bata (footwear scale), ITC (FMCG pricing power + hotel operations), Tata Motors (EV ramp, commercial vehicle stability). Secondary: Aditya Birla Fashion, Oberoi.

    Sector Comparison: At a Glance

    Sector FY26E Growth EBITDA Margin Tailwind/Headwind Conviction
    AI & Tech 18-22% 18-21% GenAI adoption High
    Renewables 20-25% 40-45% Capex cycle, FDI High
    Defence 15-20% 16-22% Localisation, Exports High
    Pharma 10-12% 22-28% Biosimilars, Exports Medium
    Financials 12-16% 35-42% Credit growth, NPA benign Medium
    Infrastructure 12-18% 12-18% Government capex push Medium-High
    Consumer 10-14% 8-16% Consumption growth, premiumisation Medium

    What This Means for Institutional Capital Allocation

    Three practical conclusions emerge from this Indian equity sector analysis 2026:

    India’s sectoral diversification is its greatest asset. From AI to renewables to defence, the breadth of opportunity across sectors is unlike anything we’ve seen in the last two decades.

    – Arvind Kalyan, Founder & CEO, RedeFin Capital

    1. High-Growth Sectors Carry Valuation Risk
    AI/Tech and Renewables are priced for flawless execution. Single-digit NPA hiccup or missed capex milestone tanks multiples 15-20%. Quality of management and execution track records matter more than sector growth rate. TCS and Adani Green trade higher precisely because delivery is visible and repeatable.

    2. Margin Expansion Trumps Volume Growth
    Defence, Pharma, and Financials offer margin upside with lower volume volatility. A defence order won, pharma biosimilar launched, or banking NPA resolution delivers predictable margin accretion. Investors overweight growth often miss 8-12% margin uplift potential in these sectors.

    3. Sector Rotation Requires Discipline, Not Emotion
    FII selling ₹1.2 lakh Cr in 2024 created mispricing. Consumer names corrected 20-30%. Renewables and Defence derated 15-25%. Quality dislocation created entry points for DIIs deploying ₹2.5 lakh Cr+ capital. Institutional allocators who stick to sector fundamentals (capex cycles, margin cycles, macro triggers) outperform index chasers.

    Frequently Asked Questions

    Q: Is the Indian equity market overvalued at Nifty 24,000+?
    A: Nifty trades at 22-23x FY27 earnings-reasonable for 12-15% earnings CAGR and stable macro. Sector-specific valuations vary wildly. Tech trades 25-28x, Renewables 30x, Pharma 20-22x, Financials 15-18x. If sector growth justifies multiples, there’s no broad overvaluation. But index-level complacency is risky.

    Q: What’s the playbook if FII outflows accelerate further?
    A: Dislocation deepens. Quality blue chips (TCS, HDFC Bank, Titan) will underperform once-beaten micro-cap names. For institutional allocators, this is opportunity: step in when >₹50,000 Cr selling cycles occur and value indices track 15-20% discount to quality indices. Historical playbook: wait for 18-month reversal as DIIs accumulate.

    Q: Which sector has the lowest downside risk in a rate-hike scenario?
    A: Defence and Pharma. Both have structural government/external demand tailwinds independent of rate cycles. Tech and Renewables capex could compress if funding costs spike 150+ bps. Financials benefit from rate hikes (NIM expansion), but loan growth may slow.

    Q: Are emerging market flows returning to India in 2026?
    A: Unlikely in H1 FY26. Brazil and Mexico offer higher yield and less valuation risk. India re-enters flows when: (1) Nifty trades <19x FY27 earnings, (2) RBI cuts rates (likely Q3 FY26 onward), (3) FII selling exhaustion signals. Watch for 500+ bps inflows reversal into large-cap defensives and SMID-cap growth plays.

    Sector Signals to Watch

    • Tech sector: Watch Q4 FY26 guidance trends from TCS, Infosys. Commentary on GenAI billing and pipeline traction. If >₹500 Cr incremental GenAI revenue materialises, conviction rises.
    • Renewables: Monitor tariff floors. If solar bids slip below ₹1.80/kWh, capacity addition slows. Conversely, <₹1.60/kWh signals oversupply-margin compression risk.
    • Defence: Track export order wins. Each ₹500+ Cr order from Middle East, Africa, or ASEAN signals market share gains. Localisation metrics (% indigenous content) show supply-chain maturity.
    • Pharma: Monitor USFDA approvals (especially Para-IV filings), biosimilar launches, and API export data. Margin compression signals pricing pressure; margin expansion signals pricing power restoration.
    • Financials: Track CASA ratios, credit growth by segment (retail, corporate), and slippage indicators. Q2 onwards will reveal true credit cycle health post-deposit rate normalization.
    • Infrastructure: Watch for order wins, margin delivery, and working capital cycles. Project delays = red flag. On-time execution = margin upside confirmation.
    • Consumer: Monitor urban consumption surveys, e-commerce penetration trends, and category-level volume growth. Consumption resilience despite inflation signals durability.

    Internal Links: For deeper dives, see how institutional investors use equity research to make better decisions (Post 20) and India’s growth story: macro trends driving investment opportunities (Post 47).

    Key Takeaways

    • AI and deeptech attracted 58% of VC funding in 2025, signalling a structural shift in India’s startup market
    • Renewable energy capacity additions target 500 GW by 2030 – creating a massive investment pipeline
    • Defence sector indigenisation under Make in India opens ₹1.5 lakh Cr in procurement opportunities
    • Healthcare and fintech remain resilient growth sectors with proven unit economics
    • Infrastructure spending at ₹11.1 lakh Cr annually creates a multiplier effect across adjacent sectors

    Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. RedeFin Capital is not a SEBI-registered investment adviser (registration pending). All data sourced from public domain materials and official reports. Sector selection involves inherent risks. Past performance does not guarantee future results. Readers must conduct independent due diligence and consult qualified financial advisers before making investment decisions. Markets are inherently volatile; sector rotation strategies carry execution risk. This content is current as of March 2026 and subject to material change without notice.

    Sources & References

    • NSDL, FII Data, 2025
    • SEBI, Mutual Fund Data, 2025
    • NASSCOM, AI Report, 2025
    • MNRE, Annual Report, 2025
    • Ministry of Defence, Annual Report, 2024-25
    • IQVIA, India Pharma Report, 2025
    • RBI, Financial Stability Report, 2025
    • Union Budget, 2025-26
    • BCG, India Consumer Report, 2025
  • How Institutional Investors Use Equity Research to Make Better Decisions

    How Institutional Investors Use Equity Research to Make Better Decisions

    Arvind Kalyan, RedeFin Capital

    Institutional cash-₹50+ lakh Cr sloshing through Indian equities-runs on research. But try asking a fund manager what equity research actually is. Most will fumble. And individual investors? Forget it. They’re reading headlines and calling it analysis. The gap between institutional reality and public understanding is vast. Here’s what actually happens inside the black box-how research gets made, why some investors swear by it, what a proper report looks like, and why India’s mid-cap story hinges on better analysis.

    What Is Equity Research, Really?

    Strip away the jargon. Equity research answers one question: What should this company be worth? It’s systematic-combining financial models, industry intelligence, management scrutiny, and valuation work. Output: BUY, HOLD, or SELL. That’s it.

    What separates real research from noise? The model. An analyst publishes a target price-say, ₹500 per share-because a spreadsheet shows it. Current price is ₹350. That ₹150 jump (43% upside) is the bet. Everything supporting it lives in assumptions: revenue growth, margins, exit multiples. Twist one assumption, the thesis breaks. That’s why the model matters-it’s auditable. Unlike market chat, research forces you to show your work.

    600+

    SEBI-registered research analysts in India

    ₹3,000-4,000 Cr

    Annual size of India’s equity research market

    Three Types of Equity Research: Sell-Side, Buy-Side, and Independent

    Sell-Side Research (Brokerage Houses)

    Banks and brokers churn out research. Used to be free-buried in commission. Your broker published stock reports to keep you trading. Then came MiFID II. Suddenly, clients had to pay. Research decoupled from execution. Accountability shot up.

    But conflicts still lurk. If a bank’s IB team is landing advisory mandates from Company X, the research side feels pressure. 2008 made this obvious. Today-especially post-SEBI rules in India-it’s regulated. Still. A large brokerage’s equity research is rigorous because they have armies of analysts. Quality and conflicts? Both real.

    India’s SEBI cracked down in 2015-2018 (Research Analyst Regulations). No overt “you publish a BUY, we give you a mandate” deals. Still, sell-side research is built for reach, not purity. They’re selling access, not just truth.

    Buy-Side Research (Fund Internal Teams)

    Mutual funds, pension funds, insurance houses-they hire analysts to dig. These teams aren’t SEBI-regulated as “research analysts.” They’re portfolio people. They research for one reason: to build better positions. No external pressure. No marketing. A fund manager spends months building a financial model, reaches conviction, builds the position. Nobody sees the work. That’s the point. This research prints alpha.

    Independent Research (Fee-Based, Conflict-Free)

    Then there’s the pure play. SEBI-registered analysts who aren’t brokers. They don’t execute trades. They don’t land advisory mandates. They charge subscription fees to funds. Kedge (RedeFin’s equity shop) sits here. MiFID II kicked off this model. Funds wanted research with zero ties to commissions. They’d pay. Analysts delivered rigorously. Now it’s 20%+ annual growth. Institutions prefer it. Transparent model. You pay, you get unbiased output.

    Why Institutions Are Shifting to Independent Research

    Institutional money (₹50+ lakh Cr deployed) is moving cash to independent shops. Why?

    • No commission baggage: Your research fee doesn’t subsidise someone’s trading desk
    • Mid-cap coverage that actually exists: Large brokers ignore mid-caps. Independents focus there. Gaps get filled.
    • SEBI lit a fire: Regulators pushed analyst independence hard. Institutions know it.
    • Alpha lives here: Consensus research builds bubbles. Good alpha comes from non-consensus, deeply researched bets

    How Institutions Deploy Equity Research Across Four Core Functions

    1. Idea Generation

    A fund manager sees a Kedge initiation on a ₹15,000 Cr IT services firm. 25%+ revenue CAGR. 8x EV/EBITDA. Supply-chain shift tailwind from India-China stress. Thesis: “mid-tier consolidation play.” Bang. Portfolio candidate born.

    2. Due Diligence Support

    Insurance fund eyes a ₹5,000 Cr infrastructure asset. Before writing the cheque, they consume 5-10 equity reports on the company, peers, sector. Research scaffolds DD-model framework, management red-flags, regulatory exposure. No surprises on the due diligence table.

    3. Portfolio Monitoring (Thesis Validation)

    Q3 earnings hit. Margins compressed. Analyst’s model assumed stable spreads. Now what? Portfolio manager pulls the quarterly update, reassesses. Maybe trim. Maybe exit. Thesis broken. Research flags it.

    4. Sector Thesis Validation

    Kedge drops a rural India sector report. Fund manager’s thinking: should rural FMCG be overweight? Report answers. Macro-micro linkages clear. Thesis validated or killed. Positioning adjusted.

    ₹50+ Lakh Cr

    Assets under management in Indian equities by institutional investors

    20%+

    Annual growth in independent research demand post-MiFID II

    The Anatomy of a Professional Equity Research Report

    Structure matters. Here’s what professionals build:

    Investment Thesis (Front Page)

    One page. Boom. Example: “ABC Consumer is a BUY at ₹250, target ₹350 in 18 months. Why: strong brands, rural push, scale margins. Risks: input costs, competition.” That’s it. Everything else proves it.

    Company Profile & Business Model

    10-15 pages: Who are they? What do they sell? To whom? Revenue drivers. Cost levers. Competitive moat or lack thereof.

    Financial Analysis & Historical Trends

    5-10 pages: Five years of data. EBITDA progression. ROIC. Free cash flow. Is this story real or accounting magic? Analysts sniff it out.

    Financial Model & Forecasts

    5-10 pages: Revenue, EBITDA, capex, working capital, FCF for 5-10 years out. Assumptions shown. “Revenue CAGR 15%, EBITDA margin steady at 22%.” No black boxes.

    Valuation (DCF + Relative Comps)

    5-8 pages: DCF model output with sensitivity tables (what if discount rate moves? what if terminal growth shifts?). Peer multiples. P/E, EV/EBITDA, P/B. Both methods converging on a price band.

    Risk Factors & Thesis Vulnerabilities

    3-5 pages: What breaks the thesis? Input costs spike. Regulation changes. Margin compression. Analyst owns the gaps upfront.

    Target Price & Rating

    1 page: 12-18 month target (DCF or comps), BUY/HOLD/SELL rating, risk/reward stated.

    “Nobody buys a report. They buy conviction backed by track record. Did your target prices hit? Did your earnings calls nail it? Did you flip your view when the facts shifted? That’s credibility. Everything else is noise.”

    – Institutional portfolio manager, multi-asset fund

    Key Metrics Institutions Use to Evaluate Research Quality

    Target Price Hit Rate

    Did the analyst’s 12-18 month targets actually work? Within ±15% of reality? Or consistently wrong? Below 50% hit rate? You’re not a skilled analyst. You’re a coin flip.

    Earnings Estimate Accuracy

    Analyst publishes EPS guidance. Compare to actual results. How often do they miss? Do they revise constantly (reactive) or predict ahead (predictive)? Pattern matters.

    Sector Coverage Depth

    Large-caps get 100 analysts. Mid-caps? Crickets. India’s mid-cap universe (₹10,000-50,000 Cr: 150+ stocks) is criminally under-covered. Analysts digging here build franchise value with institutions.

    Idea Originality & Non-Consensus Calls

    Everyone calling BUY on a stock? Herd behaviour. Bubbles form. Smart analysts stake contrarian positions early-with work backing it. A SELL on a favourite beats the 50th BUY recommendation every time.

    150+

    Mid-cap stocks in NSE Nifty Midcap 150 Index

    5-7%

    Annual outperformance of Nifty Midcap 150 vs. Nifty 50 (5-year CAGR)

    SEBI Research Analyst Regulations & India’s Compliance Framework

    India has teeth in its rulebook. SEBI’s Research Analyst Regulations (2015, amended 2018) govern the space:

    • Registration is mandatory. Anyone publishing research must be SEBI-registered. 600+ analysts on record as of 2025.
    • Conflict disclosure required. Holding shares in Company X? Earning advisory fees? You declare it. Every report.
    • No quid pro quo. Can’t be “we’ll rate your stock BUY if you give us the M&A mandate.” Explicit ban.
    • Standard disclaimers. Past performance doesn’t guarantee future returns. Liability limits. Every report, same boilerplate.
    • Analyst pay not tied to ratings. Your bonus can’t move because you called a SELL. Prevents gaming.

    Kedge (RedeFin’s equity shop) operates as SEBI-registered RAs. Everything meets conflict standards. Everything is institutional-grade.

    The Mid-Cap Opportunity & Research Gap

    Mid-cap India (₹10,000-50,000 Cr) has crushed Nifty 50-5-7% annual outperformance over five years. Yet less than 30% of research coverage. Massive gap. This is where money is made.

    Kedge digs here: mid-cap industrials, IT services, consumer, healthcare, fintech. Why? (1) Real growth, (2) prices misprice constantly, (3) deep analyst work unearths 10-baggers. Brokers chase mega-caps. This space is mine.

    From Research to Action: The Institutional Workflow

    The playbook:

    1. Scan research. In-house analysts, external reports. Find thematic ideas fitting the mandate.
    2. Validate the thesis. Commission deep work. Run models. Interview management. Peer analysis. Is this real or marketing?
    3. Build position slowly. 2-8 weeks. Don’t tip off the market.
    4. Monitor quarterly. Subscribe to updates. Earnings previews. Is the thesis still intact?
    5. Exit when thesis breaks. Fundamentals re-rated. Fair value hit. Position trimmed or unwound.

    Research feeds conviction. Conviction feeds execution. Execution feeds returns. Quality of research directly moves alpha. Garbage in-garbage out.

    Why Independent Research Matters More Than Ever

    Three forces pushing institutions toward independents:

    1. MiFID II Unbundled Everything

    Europe’s rule (2018): clients pay separately for research. Decouples research from trading commissions. Global shift. Institutions now expect conflict-free analysis, not bundled brokerage giveaways.

    2. Institutional AUMs Exploding

    ₹50+ lakh Cr in Indian equities managed by funds, pensions, insurers. They can afford premium research. They demand specificity. Boutique analysts deliver. Large brokers can’t.

    3. Mid-Cap Coverage Desert

    Nifty Midcap outperforms. Yet it’s under-researched (brokers chase mega-caps). Independents fill the void. Rigorous, thematic analysis on 150+ stocks nobody else touches.

    Key Takeaways

    • Equity research is systematic company analysis that produces fair value and investment recommendations for institutional and professional investors.
    • Three research types serve different institutional needs: sell-side (broker-published, execution-linked), buy-side (internal to funds, proprietary), and independent (paid, conflict-free).
    • Institutions evaluate research on target price accuracy, earnings estimate quality, sector coverage depth, and idea originality.
    • India’s 600+ SEBI-registered analysts operate under strict conflict-of-interest rules, creating a regulated, professional market.
    • Mid-cap India (₹10,000-50,000 Cr) is under-researched but outperforming large-cap indices; this gap creates alpha opportunities for rigorous analysts.
    • Independent, paid research is growing 20%+ annually as institutions value conflict-free, deep analysis for investment decisions.

    Frequently Asked Questions

    Q1: Is equity research still relevant post-passive investing boom?

    Yes. While passive (index) investing has grown, active management still controls ₹25+ lakh Cr in Indian equities. These managers need research to generate alpha. Also, passive investing itself relies on research: index methodologies reflect analyst judgements about sector weighting, constituent selection, and earnings forecasts.

    Q2: How do institutions decide which research to subscribe to?

    Institutions evaluate: (1) analyst track record (hit rate, accuracy), (2) sector expertise and coverage gaps relevant to their mandate, (3) research depth (full models vs. Surface-level notes), and (4) cost relative to perceived alpha upside. A mid-cap specialist with 60%+ target price accuracy may command higher fees than a consensus large-cap analyst.

    Q3: Can individual investors access institutional equity research?

    Partially. Sell-side research from brokers is often free or subsidised to retail clients. Independent research is typically subscription-based and pitched to institutions, but some analysts (including Kedge) publish curated insights for retail audiences. DIY investors should be cautious about free research (check for conflicts) and favour sources with transparent track records and SEBI registration.

    Q4: What is the difference between equity research and stock tips?

    Equity research is systematic, model-backed analysis with documented assumptions and valuation. A “stock tip” is typically anecdotal, unmodelled, and unaccountable. Research should always show its work (assumptions, model, valuation methodology); tips rarely do. If you can’t see the financial model and assumptions, it’s not research-it’s speculation.

    What’s Next?

    Institutional investors looking to deepen their equity research discipline should consider:

    • Subscribing to sector-specific independent research aligned with portfolio thematic (e.g., rural India, infrastructure, IT services).
    • Building in-house research capability for non-consensus or under-covered stocks where information asymmetry creates alpha.
    • Auditing broker research for conflicts and consistency-compare sell-side recommendations to actual trading flows.
    • Engaging with research analysts directly (earnings calls, management meetings) to stress-test assumptions and build conviction.

    The institutions that win are those that treat research not as a commodity but as a core input to investment discipline. Better research input. Better decision-making. Better returns.

    Disclaimer: This article is educational in nature and does not constitute investment advice. Equity research methodologies, institutional workflows, and regulatory frameworks described are based on publicly available data and industry practice as of March 2026. Individual investors should conduct independent due diligence and consult registered financial advisers before making investment decisions. All financial figures and market data cited are sourced from SEBI, NSE, ICRA, and related public databases; performance data is historical and not indicative of future results. RedeFin Capital’s Kedge equity research operates within SEBI Research Analyst Regulations and maintains strict conflict-of-interest standards.

    Sources & References

    • SEBI, Intermediary Data, 2025
    • SEBI, Research Analyst Data, 2025
    • SEBI, Mutual Fund Statistics, December 2025
    • CFA Institute, Global Research Survey, 2025
    • NSE, Market Data, 2025
    • NSE, Index Performance Data, 2025

Powered by
►
Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.
None
►
Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.
None
►
Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.
None
►
Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.
None
Powered by